Hesselink, D.A.

patient cyclosporine transplant tacrolimu transplantation study kidney cyp 3a concentration recipient pharmacokinetic effect transplant recipients cyp 3a genotype group genotype liver rejection malaria polymorphism allele expression cyp 3a allele disease level blood result treatment difference exposure function nephrotoxicity therapy p-glycoprotein clin pharmacol month clearance variability abcb 1 inhibitor pharmacol pharmacogenetic calcineurin kidney transplant recipients table incidence analysis protein monitoring heart liver transplant recipients model cyclosporine pharmacokinetics requirement falciparum value allograft kidney transplantation t-cell chapter side effects activity c 2 levels plasma target tacrolimus dose requirement mycophenolic variant heart transplant recipients mycophenolic acid abcb 1 genotype van gelder t polycystic kidney disease hesselink addition cyclosporin falciparum malaria trial calcineurin inhibitors mycophenolate mofetil